title: Impaired kidney allograft function following ezetimibe therapy.
abstract: Although ezetimibe therapy has been shown to be effective in lowering serum cholesterol level, it has not been reported to affect serum cyclosporine level in transplant recipients. Here, we describe a kidney transplant recipient who experienced acute kidney allograft dysfunction after ezetimibe prescription. Our patient showed an increase in serum creatinine level as well as a decrease in serum cyclosporine levels 1 month after taking ezetimibe. This suggests that ezetimibe may interact with cyclosporine and decrease its serum level resulting in allograft dysfunction. In this regard, careful monitoring of kidney function along with the serum cyclosporine level in kidney allograft recipients is recommended when cyclosporine is co-administered with ezetimibe.
authors.affiliation: Department of Internal Medicine, Shahid Sadoughi Medical University, Yazd, Iran. dr_nori_majelan@yahoo.com
authors.forename: Nader
authors.initials: N
authors.lastname: Nouri-Majalan
authors.forename: Sara
authors.initials: S
authors.lastname: Moghaddasi
authors.forename: Reza
authors.initials: R
authors.lastname: Majidi
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001384:Azetidines / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000097:blood; D000069438:Ezetimibe; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D055031:Primary Graft Dysfunction / Q000139:chemically induced*
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D016572:Cyclosporine; D003404:Creatinine; D000069438:Ezetimibe